NewsBenzingaWedbush维持对Viridian Therapeutics的“跑赢大盘”评级，将目标价上调至44美元 Wedbush维持对Viridian Therapeutics的“跑赢大盘”评级，将目标价上调至44美元 Benzinga 2026.11.10 15:27 (GMT+0) Open on Benzinga Other news Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44 Wells Fargo Maintains Overweight on Monday.Com, Lowers Price Target to $100 Wedbush Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $7 Oracle Stock Hovers Around the Flatline: What's Going On? Jupiter launches token baskets, yield vaults and other new products, expanding beyond trading Immunome Analysts Cut Their Forecasts After Q3 Results
